Industry News


Industry News
Global Trends
Events Calendar
Web Links

Web Gallery

Advertising  Info



HMD launches India’s First Dispovan Insulin Pen Needle

Hindustan Syringes & Medical Devices (HMD) one of the largest manufacturers of Disposable Syringes in the World and the largest for Auto Disable syringes has today launched most revolutionary and pioneering, India’s First “Made in India” Dispovan Insulin Pen Needle” to provide better comfort for people with diabetes at the 4th Medical Expo Indore 2018. The Dispovan Insulin pen needle is a precision engineered, yet affordable sterile single use pen needle, which can be universally fitted on all international brands of Insulin Pens. With features like, ergonomic shape for improved skin contact and grip, extra thin wall, multi-bevel, tapered point, Dispovan Insulin pen needle is designed and manufactured by HMD with intent to offer a much less painful injection experience for diabetic patients.

According to Mr. Rajiv Nath, Jt. Managing Director of Hindustan Syringes & Medical Devices (HMD), “We are particularly excited about the prospects of our latest offering ” Dispovan Insulin Pen Needle” manufactured in our state of the art manufacturing facilities, which will end India’s import dependency and the monopoly of BD. Patients will now be able to access an affordable quality product, which they need not reuse because it is expensive. We have received excellent feedback and clinical acceptance from the end users of a comfortable injection and glad that our investments in high end technology are giving us a competitive edge.”

“With the launch of ‘Dispovan Insulin Pen Needle’ we will contribute towards our ongoing commitment of making healthcare affordable for common people in India” said Mr. Pardeep Sareen, Chief General Manager-Marketing of HMD.

“Why reuse a pen needle”, he quipped “when Dispovan makes it affordable for single use? Reuse of a Insulin pen needle could increase the following :

• Bacterial growth on the needle – Risk of injection
• Experiencing pain when injecting
• Risk of lipohypertrophy (lumpy skin) occurring
• Risk of the very fine tip of the needle breaking off

The above stated risks will grow with each reuse”, he adviced.

Dispovan Insulin Pen Needle is manufactured at HMD’s Faridabad-Ballabgarh plant. The new plant is spread on an area of 5.5 acres and will have the capacity to initially produce over 100 million units per annum of ‘Dispovan Insulin Pen Needle’ to meet the rising export and domestic demand for its new technology. Every Needle point is checked online by a Digital Vision Camera System for a defective, blunt needle point and such needles, which can be potentially painful are rejected automatically on line, he explained. The proprietary dry silicon coating used by us makes the needle surface slippery to ensure comfortable injection.

Dispovan Insulin Pen Needle has needle gauge option of 31G & 32G with needle length of 5mm & 4mm respectively and comes in purple and green colour shade to enable visual recognition of needle size.

The pricing of the Becton, Dickinson and Company (BD) pen needle is Rs.14 MRP whereas HMD has initially kept the MRP of its’ Dispovan pen needle for Rs.12. Dispovan pen needle is economical to patient by at least 15 %, as compared to imported pen needles. Unlike prices of imports that are volatile and linked to ever changing exchange rates and steady devaluation of Indian rupee that makes imports expensive, the made in India product has relatively stable pricing.

MTaI Asks Govt To Commit Definitive Package On Developing Healthcare Infrastructure

The Medical Technology Association of India (MTaI) has recommended to the government to commit a definitive package on developing healthcare infrastructure, procurement and to increase fiscal spend to 2% of GDP in 2020-21 and 3% by 2021-22.

The entire healthcare continuum from providers to medical device suppliers have been hit by cash crunch due to increase in import duty, rupee devaluation against dollar, increased transport cost in the COVID situation due to surge prices, reduced cash flow due to non-payment of dues and decrease in revenue due to stoppage of elective procedures.

MTaI has therefore urged the government to provide some relief and help the healthcare sector sustain in these testing times. It has recommended to announce special fiscal package to release all pending payments to maintain cash flow to the providers and suppliers. It has also recommended to increase patient affordability by reducing customs duty, health cess and GST on medical devices which cannot be made in India in the short and medium term, with a view to handle the COVID-19 crisis. Other recommendations include restarting the elective surgeries in all zones, with special initiative for transportation of patients and ensuring stringent safety guidelines. There is also a need to bring down aviation fuel cost so that cost of logistics in shipping devices across the country is reduced.

MTaI chairman and director general Pavan Choudary said, "In our opinion, Aatma Nirbharta (self- reliance) in medical technology sector would be achieved, when we can make competitive products in India. When people of India can be treated in India without having to travel abroad and spending precious foreign exchange, when the tertiary care facilities will expand in the government sector too, when R&D flourishes to handle our problems as well as respond to global opportunities, when every Indian healthcare workers gets trained as well as his best global counterpart."

The government has expressed its intention to create a surplus capacity in healthcare infrastructure. The plan to increase public expenditure on healthcare and ramp up health and wellness centres in remote areas will certainly help the needy in availing health services, especially since India’s spend on healthcare is only 1.3 per cent of its GDP and needs severe bolstering. There is a need to carve out a concrete plan on building healthcare infrastructure at tertiary levels both in the government and private sectors, create more diagnostic centres and increase procurement of antibiotics and medical devices among others.

He further added, "We believe that spending on healthcare can increase GDP by increasing productivity with reduced loss of man-days due to sickness. Also healthcare investment can increase employment opportunities in service provider segment like hospitals with increased number of clinicians, paramedics and nurses. The employment opportunities in the industries supporting it like medical technology and pharmaceuticals will also be increased with more spend on manufacturing, supply chain and R&D. It is clearly established that countries with higher spend on healthcare have better per capita income with higher productivity." MTaI is an association of research-based medical technology companies who have made remarkable investments in manufacturing, R&D and health care workers training in India.

Other News

NCL, BEL To Produce Medical Devices For Tackling Pandemic
Gujarat FDA Issues Licenses To 12 More Oxygen Manufacturers To Produce Medical Oxygen To Cater To COVID-19 patients





Back | Back To Top | Previous | Next